ArticleJournal of the National Cancer Institute2014
Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.
Open access · greenAbstract read
In one paragraph
Article in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Arterial Enhancement Fraction-Spectral CT-Based Model as Part of Prediction Model in BRAFDiagnostics (Basel, Switzerland) · 2025Article
- BRAF mutations and targeted therapy in unclassified pericytic tumors: insights from genetic analysis and clinical response.BMC cancer · 2025Article
- Pericytes in hematogenous metastasis: mechanistic insights and therapeutic approaches.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Association between genetic mutations in lung adenocarcinoma and adult body mass index: a retrospective cohort study.Frontiers in oncology · 2025Article
- Myopericytoma in the oral cavity: a rare case report and literature review.International journal of clinical and experimental pathology · 2025Article
- Malignant myopericytoma originating from the colon: A case report.World journal of gastrointestinal surgery · 2024Article
- Pediatric upper lip myopericytoma: a case report and comprehensive review.BMC oral health · 2024Review
- Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.The Journal of clinical endocrinology and metabolism · 2021Article
- A Molecular Reappraisal of Glomus Tumors and Related Pericytic Neoplasms With Emphasis on NOTCH-gene Fusions.The American journal of surgical pathology · 2020Article
- Article
- Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Nuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics.Head and neck pathology · 2017Article
- Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation.The American journal of surgical pathology · 2017Article
- Article
- VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.EMBO molecular medicine · 2017Article
- The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met.Oncotarget · 2016Article
- SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.Oncotarget · 2015Article
- Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer.Cancer letters · 2015Article
- Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening.Oncotarget · 2015Article
- Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker.Discoveries (Craiova, Romania)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 3 countries.
Peter M SadowDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Carmen PrioloDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Simona NanniDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Florian A KarrethDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Mark DuquetteDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Roberta MartinelliDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Amjad HusainDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
John ClohessyDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Heinz KutznerDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Thomas MentzelDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Christopher V CarmanDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Antonella FarsettiDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Elizabeth Petri HenskeDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Emanuele PalescandoloDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Laura E MacconaillDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Seum ChungDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Guido FaddaDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Celestino Pio LombardiDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Antonina M De AngelisDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Oreste DuranteDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
John A ParkerDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Alfredo PontecorviDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Harold F DvorakDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Christopher FletcherDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Pier Paolo PandolfiDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Jack LawlerDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF).
Carmelo NuceraDepartment of Pathology, Massachusetts General Hospital (PMS) and Department of Medicine, Brigham and Women's Hospital (CP, EPH), Harvard Medical School, Boston, MA; Unit of Endocrinology, Department of Medicine, A. Gemelli, Catholic University, Roma, Italy (SN, AP); Division of Cancer Genetics, Department of Medicine (FAK, JC, PPP) and Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Cancer Biology and Angiogenesis, Department of Pathology, Center for Vascular Biology Research (MD, CN), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine (RM, CVC) and Department of Pathology (AH, HD, JL), Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA; Dermatopathologische Gemeinschaftspraxis, Siemensstrasse, Friedri chshafen, Germany (HK, TM); National Research Council (CNR-IBCN) and Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy (AF); Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (EP, LEM); MIT/Broad Institute, Cambridge, MA (EP, LEM); Department of Plastic and Reconstructive Surgery, National Health Insurance Service Ilsan Hospital, Ilsan, Korea (SC); Department of Pathology (GF) and Department of Surgery (CPL), A. Gemelli, Catholic University, Roma, Italy; Department of Experimental and Clinical Medicine (AMDA) and Unit of Radiotherapy (OD), University of Catanzaro, Italy; Department of Nuclear Medicine, Beth Israel Deaconess Medical Center (JAP); Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (CF). cnucera@bidmc.harvard.edu.
Harvard University Press · USCenter for Cancer Research · USMagna Graecia University · ITAgostino Gemelli University Polyclinic · ITNational Health Insurance Service · KR
Funding
Training Program in Angiogenesis &InflammationT32HL007893 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI DVORAK, HAROLD FISHER · 1998 to 2017
$5.5MBRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progressionR01CA181183 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI NUCERA, CARMELO · 2014 to 2018
$1.8MMetastatic protein network in BRAFV600E positive human thyroid cancersR21CA165039 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI NUCERA, CARMELO · 2012 to 2013
$407kNCI NIH HHS 1R01CA181183-01A1NCI NIH HHS 1R21CA165039-01A1NCI NIH HHS R01 CA181183
Abstract
Myopericytoma (MPC) is a rare tumor with perivascular proliferation of pluripotent stem-cell-like pericytes. Although indolent, MPC may be locally aggressive with recurrent disease. The pathogenesis and diagnostic biomarkers of MPC are poorly understood. We discovered that 15% of benign MPCs (thyroid, skin; 3 of 20 samples) harbored BRAF(WT/V600E); 33.3% (1 of 3 samples) of BRAF(WT/V600E)-MPCs were multifocal/infiltrative/recurrent. Patient-MPC and primary MPC cells harbored BRAF(WT/V600E), were clonal and expressed pericytic-differentiation biomarkers crucial for its microenvironment. BRAF(WT/V600E)-positive thyroid MPC primary cells triggered in vitro (8.8-fold increase) and in vivo (3.6-fold increase) angiogenesis. Anti-BRAF(V600E) therapy with vemurafenib disrupted angiogenic and metabolic properties (~3-fold decrease) with down-regulation (~2.2-fold decrease) of some extracellular-matrix (ECM) factors and ECM-associated long non-coding RNA (LincRNA) expression, with no effects in BRAF(WT)-pericytes. Vemurafenib also inhibited (~3-fold decrease) cell viability in vitro and in BRAF(WT/V600E)-positive thyroid MPC patient-derived xenograft (PDX) mice (n = 5 mice per group). We established the first BRAF(WT/V600E)-dependent thyroid MPC cell culture. Our findings identify BRAF(WT/V600E) as a novel genetic aberration in MPC pathogenesis and MPC-associated biomarkers and imply that anti-BRAF(V600E) agents may be useful adjuvant therapy in BRAF(WT/V600E)-MPC patients. Patients with BRAF(WT/V600E)-MPC should be closely followed because of the risk for multifocality/recurrence.
Indexed as
MutationAngiogenesis InhibitorsBiomarkers, TumorCell Line, TumorCell ProliferationGenotypeGlutamic AcidHemangiopericytomaHumansIndolesMass SpectrometryNeoplasm Recurrence, LocalPericytesProto-Oncogene Proteins B-rafSulfonamidesThyroid NeoplasmsAngiogenesis InhibitorsBiomarkers, TumorBRAF protein, humanGlutamic AcidIndolesProto-Oncogene Proteins B-rafSulfonamidesValineVemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.